1. Fight fire with fire! Herpes virus “turns into” cancer nemesis
UK scientists presenting a paper at the recent European Society for Medical Oncology (ESMO) 2022 show that their findings suggest that a genetically modified herpes virus may give rise to a virus that has exhausted all others Therapeutic cancer patients offer hope: Significant efficacy was shown in a trial involving 39 patients.
The virus, called RP2, is a genetically modified herpes simplex virus that fights advanced cancers in a “chain attack”: destroying their cells first, then allowing the immune system to Play a role. Specifically, when RP2 is injected directly into the tumor, it multiplies inside the cancer cells and then bursts the cancer cells from the inside; it also blocks a protein called CTLA-4, which acts as an immune The “brake” of the system; moreover, the engineered RP2 can produce special molecules that stimulate the immune system. (Science and Technology Daily)
2.New study: 75% of more than 150 fish in one waters off New Zealand contain microplastics
A team of researchers from the University of Otago in New Zealand found that three-quarters of the more than 150 wild fish caught in the waters off southern New Zealand contained microplastics.
Researchers used microscopy and Raman spectroscopy to study samples of 155 marine fish of 10 commercially important species caught off the Otago coast over a year and found that 75% were studied Marine fish contain microplastics, with an average of 2.5 microplastic particles detected in each fish, and 99.68% of the identified plastic particles are smaller than 5 mm in size. Microplastic fibers are the most common type.
The study found similar levels of microplastics in fish living at different depths in these waters, suggesting that microplastics are ubiquitous in the waters studied. The researchers say further research is necessary to determine the risks to human health and ecology from eating plastic-contaminated fish.
The research is published in the new issue of the UK’s Marine Pollution Bulletin. (World Wide Web)
3. Sino Biopharmaceutical (01177.HK): Class I new drug “TDI01” approved for clinical trials against COVID-19
Recently, China Biopharmaceutical (01177.HK) announced that the Class I innovative drug “TDI01” independently developed by the company’s subsidiary Beijing Tide Pharmaceutical Co., Ltd. has been released on September 23, 2022 It was approved by the State Food and Drug Administration to conduct clinical trials of new coronary pneumonia. TDI01 is the world’s first small-molecule innovative drug that inhibits the infection of host cells by the novel coronavirus by highly selectively inhibiting ROCK2 kinase, thereby achieving a significant anti-nCoV effect.
TDI01 has previously been approved for clinical trials in idiopathic pulmonary fibrosis in China and the United States, and in China for pneumoconiosis. COVID-19 is the third indication approved for clinical trials, and the Group will continue to explore the application of TDI01 in more indications. (Source: Gelonghui)
4.U.S. reports nearly 25,000 monkeypox cases, may actually be more
The U.S. Centers for Disease Control and Prevention updated data on the 23rd that the United States has reported a total of 24,846 cases of human infection with monkeypox virus (hereinafter referred to as monkeypox cases), ranking first in the world.
The latest data shows that the top three areas in the United States for the number of reported monkeypox cases are California, New York, and Florida, with 4,886 cases in California.
Although the current increase in monkeypox cases in the United States is down from its peak in August, there are still about 200 new infections per day, according to The New York Times. The total number of monkeypox cases in the United States is more than one-third of global cases. (China News Service)